CEACAM5 and medullary thyroid gland carcinoma: CEA targeting using murine or chimeric anti-CEA bispecific antibodies and pre-targeted hapten-peptides labelled with 111In or 131I has been also developed for radioimmunotherapy in relapsed MTC (Bodet-Milin et al. 2016) (Table 2).